Fig. 5

Survival of patients with IPF with or without switching antifibrotics, as evaluated from diagnosis of IPF. Survival of patients with IPF with or without antifibrotic switching evaluated from diagnosis of IPF (A). Switch-IPF versus Non-switch-IPF Continued cases versus Non-switch-IPF Discontinued cases (B). P values were determined by the log-rank test. Cumulative survival probabilities from diagnosis of IPF were calculated. An event was defined as death from any cause and patients who were lost or still alive were censored at the last follow-up date